RESEARCH ARTICLE

Improved islet recovery and efficacy through co-culture and co-transplantation of islets with human adipose-derived mesenchymal stem cells

Anissa Gamble¹,²,³, Rena Pawlick¹, Andrew R. Pepper¹,²,³,⁴, Antonio Bruni¹,²,³,⁴, Adetola Adesida⁵, Peter A. Senior⁶,⁷,⁸, Gregory S. Korbutt¹,², A. M. James Shapiro¹,²,³,⁴,⁵,‡

¹ Alberta Diabetes Institute, University of Alberta, Edmonton, AB, Canada, ² Department of Surgery, University of Alberta, Edmonton, Alberta, Canada, ³ Members of the Canadian National Transplant Research Project (CNTRP), Edmonton, AB, Canada, ⁴ Clinical Islet Transplant Program, University of Alberta, Edmonton, AB, Canada, ⁵ Department of Medicine, University of Alberta, Edmonton, Alberta, Canada

Abstract

Islet transplantation is an established clinical procedure for select patients with type 1 diabetes and severe hypoglycemia to stabilize glycemic control. Post-transplant, substantial beta cell mass is lost, necessitating multiple donors to maintain euglycemia. A potential strategy to augment islet engraftment is the co-transplantation of islets with multipotent mesenchymal stem cells to capitalize upon their pro-angiogenic and anti-inflammatory properties. Herein, we examine the in vitro and in vivo effect of co-culturing murine islets with human adipose-derived mesenchymal stem cells (Ad-MSCs). Islets co-cultured with Ad-MSCs for 48 hours had decreased cell death, superior viability as measured by membrane integrity, improved glucose stimulated insulin secretion and reduced apoptosis compared to control islets. These observations were recapitulated with human islets, albeit tested in a limited capacity. Recipients of marginal mouse islet mass grafts, co-transplanted with Ad-MSCs without a co-culture period, did not reverse to normoglycemia as efficiently as islets alone. However, utilizing a 48-hour co-culture period, marginal mouse islets grafts with Ad-MSCs achieved a superior percent euglycemia rate when compared to islets cultured and transplanted alone. A co-culture period of human islets with human Ad-MSCs may have a clinical benefit improving engraftment outcomes.

Introduction

Islet transplantation is a therapeutic procedure that can restore endogenous insulin production and maintain euglycemia for a sustained period in patients with difficult to control type 1 diabetes.
by the Alberta Innovates - Health Solutions (AIHS) Postdoctoral Fellowship Grant 201400496. A. Bruni is supported by Canadian Institutes of Health Research - Proof of Principle Grant 144255 and Stem Cell Network (SCN). A.A. is supported by Canadian Institutes of Health Research - Operating Grant (CIHR MOP 125921). A.M.J. Shapiro is supported through SCN Grant NCESCN CTRA FY17/CT5 and NCESCN DTRA FY17/DT6; AIHS Proof of Principle 144255 and Collaborative Research and Innovation Opportunities (CRIIO) Team funding Grant 201201154; the Juvenile Diabetes Research Fund Canadian Clinical Trial Network (JDRF CCTN) and the Diabetes Research Institute Foundation Canada (DRIFCan).

**Competing interests:** The authors have declared that no competing interests exist.

diabetes mellitus (T1DM). The recent Clinical Islet Transplant Consortium’s, National Institute of Health (NIH) sponsored phase 3 trial demonstrated islet transplantation’s ability to stabilize glycemic control in select patients with T1DM presenting hypoglycemia unawareness where the primary end-point revealed 88% and 71% of recipients maintained euglycemia for 1-year and 2-years post-islet transplant respectively [1]. This Federal Drug Administration (FDA)-Biologics License Application enabling study may allow product licensure for islet transplant, facilitating reimbursement through insurance in the USA. Despite its apparent success, this procedure is not without limitations. A major challenge is overcoming suboptimal acute engraftment, where up to 60% of the initial transplanted islet mass is potentially lost due to innate instant blood-mediated inflammatory reaction (IBMIR), delayed re-vascularization, or hypoxic stress [2–5]. Multiple islet infusions are therefore often required to maintain periods of insulin independence. Co-transplantation of islets with multipotent stem cells (MSCs) is a potential strategy to mitigate early islet cell loss in culture and after transplantation [6, 7]. MSCs are ubiquitous throughout cell types, and their capacity for self-renewal and differentiation into cells of mesoderm lineage includes adipocytes, chondrocytes, osteoblast and myocytes [8]. Previous studies have demonstrated the ability of MSCs to augment islet function, in part due to MSC’s immunomodulatory and trophic properties, and their ability to secrete several paracrine factors [9–11]. Notably, MSCs modulate angiogenesis through gene expression of cytokines, including vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs), transforming growth factor-βs (TGF-βs) and Annexin-1 (ANXA1) [12–14]. MSCs can modulate the secretion of cytokines and promote the concentration of growth factors at the islet engraftment site and may aid neovascularization [15, 16].

In the clinical islet allograft setting, islets undergo an obligate culture period of up to 72 hours before transplantation. The culture period facilitates recipient conditioning, and may allow for transplantation of a more immunologically quiescent graft [17, 18]. Conversely, culture may be detrimental to islet survival due to limited nutrients, and exposure to oxidative, hypoxic, and inflammatory stressors [19]. These stressors lead to impaired islet viability and decreased cell mass. In addition, islet endothelial cells are compromised during the islet isolation and culture process that diminishes islet recovery and function prior to transplantation [20, 21]. During isolation, islets are stripped of their native vascularization and rely on diffusion of nutrients and oxygen to survive. Moreover, the intra-islet endothelial cells rapidly decline to 5% by 4 days post culture [20]. The disrupted vascular supply hinders the post-transplant revascularization process. Over this period, insufficient vascularization causes increased cell death and graft failure due to inadequate nutrient delivery and prolonged ischemia [21]. In consequence, multiple donors and infusions are often required to maintain recipient insulin independence [19, 22, 23]. To decrease donor demand, it has been shown co-culturing islets with human bone marrow-derived MSCs or mouse adipose-derived MSCs (Ad-MSCs), for an extended period, can augment islet function and improve islet engraftment post-transplant [24–26].

In the present study, we explored the use of human Ad-MSCs co-cultured with murine and human islets for 48 hours at islet to Ad-MSC ratios of 1:300 [24] and 1:2000 [25]. We hypothesize co-culturing islets with human Ad-MSCs will improve islet recovery, islet function and augment engraftment outcomes.

**Materials and methods**

**Murine pancreatectomy and islet solation**

Pancreatic islets were isolated from 8- to 12-week-old BALB/c mice (Jackson Laboratories, CA) and housed under conventional conditions in accordance with the Canadian Council on
Animal Care. All experimental procedures were approved by the University of Alberta Research Ethics and Animal Use Committee (Study ID: AUP0000331). Prior to pancreatectomy, the common bile duct was cannulated and the pancreas was distended with 0.125 mg/mL cold Liberase TL Research Grade enzyme (Roche Diagnostics, Laval, QC, CA) in Hanks balanced salt solution (Sigma, St. Louis, MO, USA). Pancreas digestion was continued in a 37°C water bath for 14 minutes with light agitation. After the pancreatic digestion phase, islets were purified using histopaque-density gradient centrifugation (1.108, 1.083 and 1.069 g/mL, Sigma, St. Louis, MO, USA). Upon purification, islets were placed in Connaught Medical Research Laboratories (CMRL-1066) (Corning-cellgro, Manassas, VA, USA) supplemented with 10% fetal bovine serum, 1% L-glutamine (200 mmol/L, Sigma, St. Louis, MO, USA), 1% sodium pyruvate (100 mmol/L, Sigma, St. Louis, MO, USA), 1% non-essential amino acid 100x (Sigma, St. Louis, MO, USA) and 100 U/mL penicillin-G and 100 μg/mL streptomycin (Sigma Aldrich Canada Co., Oakville, ON, CA) at 37°C/5%CO₂ at pH 7.4.

**Human islet isolation, purification and culture**

Human islet preparations were isolated from deceased consenting multi-organ deceased donors, as described [19], with intent for clinical transplantation. Islets were only used for research when yields failed to meet that required for a listed recipient and with research consent from donor families. Permission for these studies was granted by the University of Alberta Health Research Ethics Board (REB), Edmonton, Alberta, Canada. The REB ensures that individual research projects involving human participants, identifiable data and/or human biological material meet the requirements of the current *Tri-Council Policy Statement: Ethical Conduct of Research Involving Humans* and University policy as well as provincial, federal and other legislation and regulations, as applicable.

**Adipose derived mesenchymal stem cell expansion and culture conditions**

To prepare the human adipose-derived MSCs, infrapatellar fat pad were removed from 2 donors (18 and 25 year old males) undergoing orthopedic knee surgery at the University Hospital of Alberta, Edmonton, Canada, and processed as described before [27]. The Ad-MSCs meet the International Society for Cellular Therapy guidelines [28] and were verified through chondrogenic differentiation after stimulation with TGFbeta and dexamethasone and CD cell surface markers [27]. Ethics committee waived the need for written informed consent of patients, as specimens used in this study were intended for discard in the normal course of the surgical procedure. All research involving human participants were reviewed and approved by the University of Alberta Health REB (Study ID: PRO 00001416 and PRO 000018778).

Cryopreserved Ad-MSCs containing 2x10⁶ cells per vial were thawed upon second passage and population doubling of 4. For expansion, cells were plated in flasks containing Eagle’s minimum essential medium (MEM) (Sigma Aldrich Canada Co., Oakville, ON, CA) supplemented with 2.5 ng/mL basic fibroblast growth factor (Millipore, Etobicoke, ON, Canada), 10% fetal bovine serum, L-glutamine (2 mmol/L) (Sigma, St. Louis, MO, USA), penicillin (50 000 units) and streptomycin (50 mg) (Sigma Aldrich Canada Co., Oakville, ON, CA), HEPES (5 mmol/L) and sodium pyruvate (5 mmol/L) (Sigma, St. Louis, MO, USA) at 37°C/5%CO₂ and a pH 7.4. The medium was changed within the first 24-hours, and thereafter in 48-hours intervals. Once confluent, the cell monolayer was washed with Versene (1% EDTA in PBS; Life technologies Inc. Burlington, ON, Canada) and enzymatically detached with 0.5% trypsin-EDTA. Cells were counted and aliquoted (4 x10⁵ cells) onto 60 mm × 15 mm ultra-low adherence culture dishes (Corning, Corning, NY, USA). All samples were cultured in suspension, left to gravity settle under static conditions without agitation, stirring or mixing throughout
the 48 hours of culture. Experimental groups contained 200 BALB/c islets, and all groups (islets alone, islet: Ad-MSCs 1:300 and 1:2000) contained 5 mL of CMRL culture media for 48 hours. The MSCs isolated abided by the Mesenchymal and Tissue Stem Cell Committee of the International Society for Cellular Therapy guidelines.

**Percent islet recovery**

Post isolation and subsequently post 48-hour culture, islets were harvested and counted to determine islet yield. Aliquots from respective samples were stained with dithizone (Sigma Aldrich Canada Co., Oakville, ON, CA) and counted in triplet. The percentage of islet recovery was determined by ratio of total islets harvested 48 hours’ post-culture relative to the number of islets harvested immediately post-isolation.

**Insulin secretory activity**

Following isolation and post 48-hour culture, triplicates of 50 mouse and human islet equivalents were collected for respective groups and a static glucose-stimulated insulin secretion (s-GSIS) assay and dynamic insulin perfusion was performed. Islets were washed of residual glucose in glucose free medium, followed by incubation in RPMI-1640 (Sigma Aldrich Canada Co., Oakville, ON, CA) containing low (2.8 mmol/L) glucose, followed by high (16.7 mmol/L) glucose, each, for one hour at 37°C. The supernatant was harvested and stored at 20°C. Insulin levels were measured by an enzyme-linked immunosorbent assay (ELISA) (Mercodia, Uppsala, Sweden).

Dynamic insulin perfusion [29] was assessed by an automated perfusion system (Biorep™ Perfusion). Islets were exposed to Krebs solution containing low glucose (2.8 mmol/L, 8–16 mins), high glucose (28 mmol/L, 17–30 mins) and KCl solution (20 mmol/L KCl in 2.8 mmol/L glucose, 31–45 mins) for respective time periods. The perfusate was collected in an automated multiwell plate format and stored at -20°C until analyzed for insulin quantification by an ELISA (Alpco, Salem, NH, USA).

**Apoptosis TUNEL staining**

Apoptosis of islets was assessed quantitatively using Tdt-mediated dUTP nick-end labeling (TUNEL) staining. Prior and post-cultured islets were fixed in 4% paraformaldehyde, embedded in agar, processed and embedded in paraffin. Tissue sections were co-stained with anti-insulin antibody at 1:200 concentration (Aglent Technologies, Mississauga, ON, CA) and labeled with Rhodamine (TRITC) conjugated anti-guinea pig IgG (1:200, Jackson ImmunoResearch, West Grove, PA, USA). To identify the apoptosis, fluorescein isothiocyanate-dUTP with TdT enzyme (Promega, Madison, WI, USA) was added and counterstained with the nuclear stain, DAPI (ProLong Gold DAPI, Invitrogen, Caibsdam CA, USA). Apoptosis was determined by analyzing the number of positive TUNEL-stained cells as a percentage of both insulin and nuclei positive cells utilizing FIJI ImageJ Software (National Institute of Health, USA).

**Mesenchymal stem/stromal cell tracking**

Following isolation, MSCs were stained with a vybrant DiO cell labeling dye (ThermoFisher Scientific, Waltham, MA) dosed at 5μl per 10⁶ cells. Stained islets were distributed amongst respective groups of MSCs alone, 1:300 and 1:2000 islet to MSC ratios. Islets cultured alone did not contain MSCs. Microscopic evaluation was performed prior to culture (0 hours) and post
culture (48 hours). MSCs microscopic evaluation and quantification was performed by FIJI ImageJ Software (National Institute of Health, USA).

**Pro-inflammatory cytokine assessment**

Pro-inflammatory cytokines were analyzed from culture media post 48-hour culture. Media was assessed for mouse tumor necrosis factor (TNF)-α, KC-GRO, interferon (IFN)-γ, interleukin (IL)-1β, IL-10, IL-6 and IL-12p70 using a Mouse ProInflammatory 7-Plex Tissue Culture Kit (Meso Scale Diagnostics, Rockville, Maryland, USA). Human IL-1β, IL-12p70, IL-6, IL-8, IL-10, IL-13, TNF-α and IFN-γ cytokine analysis was demonstrated using a Human ProInflammatory Panel kit (Meso Scale Diagnostics, Rockville, Maryland, USA). The plates were loaded into an MSD-SECTOR® instrument for electrochemiluminescence analysis.

**Islet transplantation**

To induce diabetes, female and male adult (8–10 weeks, 20–30 gm) immunodeficient mice (B6.129S7-Rag1tm1Mom/J; Jackson Laboratories, CA) were administered an intraperitoneal injection of streptozotocin (175mg/kg i.p) (Sigma, St. Louis, MO, USA) in acetate phosphate buffer (Sigma Aldrich Canada Co., Oakville, ON, CA) at pH 4.5. Mice with blood glucose levels ≥18 mmol/L for two daily consecutive non-fasting blood glucose readings, were considered diabetic.

The mice were transplanted with post-isolation or post-culture mouse islets with or without the presence of Ad-MSCs (islet to Ad-MSC ratio: 1:2000) or islets alone. Islets were aspirated into polyethylene (PE-50) tubing and centrifuged. A left lateral paralumbar subcostal incision was made and islets were delivered under the left kidney capsule. Islet engraftment was assessed through non-fasting blood glucose measurements, three times per week for 60 days. Blood glucose monitoring was conducted using a portable glucometer (OneTouch Ultra 2, LifeScan, CA, USA). Two consecutive readings maintained at <11.1 mmol/L confirmed graft function and reversal of diabetes. At day 60, a recovery nephrectomy of the grafted kidney confirmed graft dependent efficacy, when animals returned to hyperglycemia (≥18 mmol/L).

**Intraperitoneal glucose tolerance test (IPGTT)**

*In vivo* glucose tolerance and islet function was assessed by an intraperitoneal glucose tolerance test (IPGTT) in euglycemic mice 6 weeks' post-transplant. The mice were fasted overnight and administered 25% dextrose intraperitoneally at a dose of 3 g/kg. Naïve normoglycemic mice served as controls. Blood glucose was monitored at baseline (t = 0), 15, 30, 60, 90 and 120 minutes’ post injection. Significance was measured as area under the curve amongst groups.

**Islet graft assessment**

Sixty days’ post islet transplant, kidney bearing grafts were removed and placed in -80˚C. Kidneys were homogenized and sonicated with 2mM of acetic acid in 0.5% of bovine serum albumin (Thermo Fisher Scientific, Waltham, MA, USA). Supernatant was collected and insulin levels were measured by an enzyme-linked immunosorbent assay (ELISA) (Mercodia, Uppsala, Sweden).

Immunohistochemistry was performed on a subset of kidneys bearing the islet grafts post 60 days’ post islet transplant and which were fixed in 10% formalin. The tissue was sectioned and upon heat retrieval, were blocked with 20% goat serum (Sigma-Aldrich, St. Louis, MI, USA), and subsequently incubated overnight at 4˚C primary antibodies guinea pig anti-insulin
(1:200, Dako, Mississauga, ON, Canada) and rabbit anti-glucagon (1:100, Abcam, Cambridge, MA, USA). The following day sections were washed and incubated with secondary antibodies for 1 hour at room temperature utilizing goat anti-guinea pig Rhodamine and goat anti-rat fluorescein (1:200 Jackson ImmunoResearch, West Grove, PA, USA) counterstained with DAPI (ProLong Gold DAPI, Invitrogen, Carlsbad CA, USA).

**Statistical analysis**

Data were analyzed using GraphPad Prism (GraphPad Software, La Jolla, CA, USA). Student t test or analysis of variance (ANOVA) was used to compare islet yield, membrane integrity, TUNEL, sGSIS and AUC for IPGTT’s and represented as scatter plots. Kaplan-Meier graft survival function curves were compared using the log-rank (Mantel-Cox) statistical method. Statistical significance was considered when p-values < 0.05. Graphical representation of data is as mean ± standard deviation (s.d) of small in vitro data sets, and standard error of the mean (s.e.m) for in vivo analysis where *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

**Results**

**Mouse islets co-cultured with human adipocyte derived mesenchymal stem cells improve in vitro function**

Murine islets co-cultured with human Ad-MSCs improved islet recovery, viability, survival and function. After 48-hour of co-culture, islets were quantified to determine islet yield. Ad-MSCs improved islet yield (Fig 1A) and demonstrated ability to adhere to the islet surface (Fig 1B). Control islets cultured alone exhibited significant islet loss (22.1 ± 10.5% islet loss) compared to both co-cultured Ad-MSC groups: 1:300 (2.7 ± 1.9%) and 1:2000 (1.1 ± 0.81%) (p<0.0001 respectively). Dual-fluorescence staining assessing islet viability revealed islets co-cultured with Ad-MSCs, 1:300 (5.9 ± 1.3%) and 1:2000 (7.1 ± 0.9%), maintained greater viability, less percentage of cell death, relative to islets cultured alone (11.7 ± 0.9%) (p<0.05, p<0.01, respectively, Fig 2A). Maximal insulin secretory function was assessed by a static glucose stimulated insulin secretion (sGSIS) assay and revealed islets co-cultured with a 1:2000 islet to Ad-MSC ratio had significantly higher stimulation index relative to islets cultured alone (islets: 0.95 ± 0.15 vs. 1:2000: 3.29 ± 0.76, p<0.05) (Table 1). A time challenged dynamic islet perifusion assay to test moment-to-moment dynamic secretory completed after 48-hour culture (Fig 2B), illustrated no statistical difference for area under the curve amongst groups (Fig 2C). Islets cultured alone had significantly increased apoptosis compared to both Ad-MSC groups. The percentage apoptosis of islets cultured alone was 34.9 ± 4.6% compared to islets cultured with MSCs at 1:300, at 19.9 ± 3.7% vs. islets cultured with MSCs at 1:2000, at 17.0 ± 3.6% (p<0.05 and p<0.001 respectively, Fig 2D and 2E).

**Pro inflammatory cytokine expression after islet transplant**

Post 48-hour culture media was collected and analyzed for murine and human pro-inflammatory cytokines (S1 Fig). Murine interleukin (IL)-2p70 expression was reduced by the presence of Ad-MSCs during culture, whereas islets cultured alone revealed increased expression (p<0.05, S1B Fig). Human and mouse IL-1β, IL-6, IL-10, and tumor necrosis factor (TNF)-α were detected but their expression amongst respective groups did not provide statistical significance (islets vs. islets +Ad-MSCs) (S1A, S1C and S1E Fig).
Co-transplantation of islets and Ad-MSCs without prior co-culture is detrimental to engraftment

To determine if a period of islet-MSC co-culture was needed, we co-transplanted islets + Ad-MSCs without prior culture. One hundred and fifty mouse islets (marginal islet mass) were isolated and co-transplanted under diabetic murine kidney capsule with or without 1:2000 Ad-MSCs combined at the time of transplant. Ten of 13 (76.9%) control islet recipients without MSCs became euglycemic at 21.0 ± 6.4 days after transplant, whereas 7 of 13 (53.8%, p < 0.001) islets + Ad-MSCs became euglycemic by 38.6 ± 6.1 days (Fig 3A and 3B). All euglycemic animals became hyperglycemic after graft recovery nephrectomy 60 days after transplant, confirming graft dependent euglycemia. Seven weeks’ post-transplant, an intraperitoneal glucose tolerance test (IPGTT) was performed on all euglycemic mice (Fig 3C) and demonstrated no significance amongst the mean area under the curve (Fig 3D).

Co-culture for 48 hours of islets and Ad-MSCs followed by co-transplantation improves engraftment

Post-isolation, islet aliquots were placed into non-adherent petri dishes and co-cultured with or without the presence of Ad-MSCs for 48 hours (1:2000 islet to Ad-MSC ratio, 48hrs co-culture period) and subsequently transplanted into diabetic mice under the kidney capsule (200 islets per recipient). Mice co-transplanted with Ad-MSCs (1:2000 islet to Ad-MSC ratio) reversed to euglycemia at a faster rate (22.3 ± 4.7 days) than the islets alone group (38.5 ± 7.6 days) (Fig 4A and 4B). As well, percent engraftment was improved in those mice transplanted with islets co-cultured with 1:2000 Ad-MSCs (islets: 9 out of 19 (47%) vs. 1:2000: 18 out of 21...
Sixty days post-transplant, all euglycemic mice returned to hyperglycemia post recovery nephrectomy. IPGTTs were performed on all euglycemic recipients 7 weeks post-transplant (Fig 4C) and there was no significant difference for area under the curve amongst respective groups (Fig 4D).

**Insulin content of kidney islet engraftment**

At 60 days post islet transplant, kidney bearing grafts were removed from both normoglycemic and hyperglycemic mice and measured for insulin content. Islets cultured for 48-hours and co-transplanted did not differ amongst respective groups (islets: 2.1 ± 0.8 ng/g vs. 1:2000: 3.1 ± 1.2 ng/g, S1 Table). Immunohistochemistry analyzing the percentage of insulin (islets: 1.8 ± 1.0% vs. 1:2000: 1.4 ± 1.1%) and glucagon (islets: 1.4 ± 0.7% vs. 1:2000: 1.4 ± 0.6%) content did not display significance amongst respective groups (S1 Table).

**Human islets co-cultured with mesenchymal cells improve in vitro function**

Human islets were examined under the same in vitro conditions as mouse islets. Although not significant, human islets cultured alone exhibited increased islet loss (12.2 ± 12.8% islet loss).
compared to both Ad-MSC groups: 1:300 (2.3 ± 2.9%) and 1:2000 (0.3 ± 0.2%) (Fig 5A). Comparable to mouse islets, Ad-MSCs adhered to human islets (Fig 5B). Membrane viability was significantly higher in islets co-cultured with 1:2000 Ad-MSCs (12.1 ± 1.6%) relative to both the 1:300 and islets cultured alone groups (23.5 ± 4.7% and 25.5 ± 2.5%, respectively) (p < 0.01, Fig 5C). Insulin stimulation index from sGSIS revealed no significant difference amongst groups (islets: 1.3 ± 0.3 vs. 1:300: 3.4 ± 0.9 and 1:2000: 4.5 ± 1.2) (Table 1).

### Discussion

In this study, we show that co-culturing mouse islets for 48 hours with human Ad-MSCs improves islet function and efficacy relative to islets cultured alone. Furthermore, we demonstrated at a limited capacity human islets co-cultured with Ad-MSCs may improve in vitro islet recovery and function. Collectively, these findings provide a fundamental basis for applications within a clinical setting. Clinical islet transplantation is restricted currently to patients with brittle T1DM that cannot be stabilized by alternative measures. Multiple intraportal islet infusions are often required to sustain euglycemia. Human islet loss during culture and intraportal transplantation is substantial, related in part to IBMIR, hypoxia, apoptosis, and other inflammatory or immune activating events [30–33]. Supplementation of islets with additives during culture may support islet function, morphology, and vitality [34–36]. It has been shown previously that human and mouse islet function can be maintained for up to 30 days after co-culture with MSCs [37, 38]. During the culture period, high doses of mouse derived MSCs and islets adhere to the edges of islets and can penetrate the islet core to form MSC-islet composites [26].

### Table 1. Mouse and human static glucose stimulated insulin secretion assay.

| Group               | Condition and Culture Period | 2.8 mM Glucose (ng/mL) | 16.7 mM Glucose (ng/mL) | Stimulation Index |
|---------------------|------------------------------|------------------------|-------------------------|-------------------|
| Mouse Islets Alone  | 0-hour culture               | 11.63 ± 1.15†          | 19.01 ± 1.78  ‖       | 1.79 ± 0.23        |
|                     | 48-hour culture              | 5.07 ± 1.32            | 12.1 ± 1.49            | 1.17 ± 0.33        |
| Mouse Islets + Ad-MSCs | 1:300 48-hour culture | 6.91 ± 1.81            | 13.20 ± 2.49 $          | 2.93 ± 0.85 $       |
|                     | 1:2000 48-hour culture       | 10.49 ± 3.96           | 26.53 ± 6.36           | 4.36 ± 1.47        |
| Human Islets Alone  | 0-hour culture               | 11.64 ± 3.9            | 39.30 ± 7.44* ‡        | 5.13 ± 1.92        |
|                     | 48-hour culture              | 3.75 ± 1.49            | 8.29 ± 2.03            | 1.48 ± 0.29        |
| Human Islets + Ad-MSCs | 1:300 48-hour culture | 6.67 ± 2.52            | 17.28 ± 3.29 ‡         | 4.54 ± 1.15        |

Data are mean ± s.e.m. of three independent experiments. In each experiment, islets were collected post isolation (0-hour culture) and post 48-hour co-culture, where groups consist of islets alone, islets with 1:300 and 1:2000 islet to human adipose-derived mesenchymal stem cell ratios. Static glucose insulin secretion assay were performed in triplets of 50 islets per group. Stimulation indices were calculated by dividing the amount of insulin released at high glucose (16.7 mM) by that release at low glucose (2.8 mM). Insulin secreted is measured in ng/mL.

- †p < 0.0001 mouse islets (0 hrs culture) vs. islets (48 hrs culture)
- ‡p < 0.05 mouse islets (0 hrs culture) vs. islets (48 hrs culture)
- ‖p < 0.01 mouse islets (0 hrs culture) vs. islets + 1:300 Ad-MSCs
- §p < 0.05 mouse islets (48 hrs culture) vs. islets + 1:2000 Ad-MSCs
- *p < 0.001 human islets (0 hrs culture) vs. islets (48 hrs culture)
- ‡p < 0.05 human islets (0 hrs culture) vs. islets + 1:2000 Ad-MSCs

https://doi.org/10.1371/journal.pone.0206449.t001
Consequentially, most studies evaluate the utilization of bone marrow derived MSCs and limited research evaluates the use of Ad-MSCs [39, 40]. Studies utilizing Ad-MSCs have shown improved islet function and reduced islet mass to reverse diabetes in rodent models [41–43]. Herein, this study examined the supplementation of mouse or human islets with human-derived Ad-MSCs during a 48-hour co-culture period to evaluate their potential clinical relevance and therapeutic benefits for human islet survival and engraftment.

Our *in vitro* observations demonstrated the ability to increase mouse islet yield, maintain vitality, cell survival and insulin secretion with the supplementation of Ad-MSCs during co-culture relative to islets cultured alone. Our observations are potentially applicable for future translation to the clinic as we demonstrated the capacity of human Ad-MSCs to also improve human islet *in vitro* potency and it can further investigate *in vivo* through the Rag−/− model. Our findings support previous literature where human islets with human-derived Ad-MSCs improved islet function *in vitro* after 72-hour culture on an engineered cell sheet [44] and improved islet efficacy in mice by pre-48-hour-hypoxic cultured human-derived Ad-MSCs intraperitoneally injected into mice [45]. Likewise, rat islets following a 72-hour post-culture with human-derived Ad-MSCs had improved islet engraftment upon intraportal co-transplantation in rats and [46]. Direct static co-culture with MSCs has the potential to release local cytokines, including VEGF and ANAX1, to promote cell survival [13, 14, 47]. We did not measure such trophic factors but in an effort to comprehend and analyze the activity of Ad-MSCs.
we collected media after 48h co-culture to quantify proinflammatory expression [48–50]. Mouse and human cytokine profiles was neither elevated nor down regulated, except for murine IL2p70. IL2p70 is a lymphocyte membrane glycoprotein (p70, IL-2RP) which aids IL-2 recruitment of lymphocytes and natural killer activity to the islet engraftment [51, 52]. The down regulation of IL2p70 may be potentially advantageous in dampening early immune responses. From these data, we interpret that MSCs are not harmful for in vitro islet survival and function, and the ability to downregulate pro-inflammatory cytokines could be dependent on in vivo function [3, 53].

Based on our in vitro observations, the 1:2000 islet to Ad-MSC ratio was used for in vivo transplantations due to their superior in vitro islet function. Without a culture period, we utilized a marginal mass dose of 150 islets, and attempted to transplant 150 islets post 48-hour culture, but due to the islet loss and subsequent decreased function, all mice transplanted maintained hyperglycemia and had to be euthanized prior to the end-point. We increased the dosage post culture to 200 islets per recipient to circumvent hyperglycemia to evaluate the islet engraftment for up to 60 days. Although islet mass transplanted was different, we have shown improved graft efficacy when islets were co-cultured with Ad-MSCs relative to islets co-transplanted with Ad-MSCs immediately after isolation without prior co-culture.

Fig 4. Efficacy of 48-hour co-culture period. Subsequent to the 48-hour co-culture period, a marginal mass of 200 BALB/c islets were counted for respective groups and co-transplanted with human Ad-MSCs under the kidney capsule of diabetic Rag−− mice. (a) Percent euglycemia displayed significant diabetes reversal for the islet-Ad-MSC group, 1:2000 (red, n = 18 of 21) versus the control group (blue, n = 9 of 19) (’p<0.05, log-rank). (b) Weekly non-fasting blood glucose measurements, regardless of euglycemia, demonstrated similar glucose profile amongst the control (blue) and 1:2000 (red) groups. (c) 7 weeks’ post-transplant an intraperitoneal glucose tolerance test was similar between groups and blood glucose area under the curve (AUC) (d) supported no significance amongst respective groups (’p>0.05, ANOVA). Naïve normoglycemic mice served as controls (n = 6) and data represented as (mean ± s.e.m).

https://doi.org/10.1371/journal.pone.0206449.g004
In this study, as a result of the islet loss in the control group compared to the islet and Ad-MSC group, the number of donor pancreata in the control group had to be increased to ensure that all groups were transplanted with a similar islet mass after 48-hour culture. We speculate improved graft function were due to Ad-MSCs formation and trophic effects during a prolonged direct cell contact of islets and Ad-MSC. The state of the Ad-MSCs prior to culture are single cells, and when transplanted MSCs could migrate away from the transplant site and therefore may not be as beneficial for engraftment. During a co-culture period, Ad-MSCs adhere to islets and one another and are more likely to remain at the engraftment site thereby increasing the probability for their trophic factors to help graft [54]. Extended culture times can reduce exocrine tissue and endotoxin carry-over [53] which may account for our observed marked improvement in islet potency after co-culture. We and others have demonstrated that MSCs can decrease islet loss, maintain islet morphology and function during co-culture with islets compared to culture of islets alone [24].

These findings are potentially readily translatable to the clinical setting, where human islets routinely undergo up to 72 hours of culture. Addition of human Ad-MSCs manufactured

---

**Fig 5. In Vitro Assessment of Human Islet Recovery, Viability and Function after Co-Culture with Adipose Mesenchymal Cells.** *In vitro* assessment of human islets co-cultured with human adipose derived mesenchymal stem cells (n = 3, isolations). (a) The percentage islet loss post 48-hour co-culture was not statistically different amongst groups (p > 0.05, ANOVA) (b) Live/dead staining by dual-fluorescence revealed human islets cultured with 1:2000 Ad-MSCs (red) had significantly improved islet viability compared to islets cultured alone (grey) and cultured with 1:300 Ad-MSCs (blue) respectively (** p < 0.01, ANOVA). (c) Microscopic imaging of labelled human adipose derived mesenchymal stem cells adhered to human islet cells after culture. Column (i) Islets cultured alone, (ii) Ad-MSCs cultured alone, (iii) 1:300 islet to Ad-MSC ratio and (iv) 1:2000 islet to Ad-MSC ratio. Rows (from top to bottom) include bright field microscopic imaging with islets stained with dithizone, fluorescence imaging displaying cell labelled mesenchymal stem cells (DiO staining) displayed in green and combined brightfield and fluorescence microscopic images. White bar represents 50μm.

https://doi.org/10.1371/journal.pone.0206449.g005
under good manufacturing conditions (GMP) during this period could be highly protective, and may decrease the need for multiple donors and risk of Human Leukocyte Antigen sensitization. Autologous MSCs offer potential promise in mitigating allo-rejection, perhaps allowing transplants to proceed with less immunosuppression and therefore less potential risk. To further elucidate the cytoprotective capacity of human Ad-MSCs our future research efforts will further explore the impact that co-culture on human islet function and engraftment.

Herein, we highlight a potential translatable strategy to protect islets in culture and early after transplantation that can increase the frequency of donor engraftment rates with the supplementation of Ad-MSC during culture.

Supporting information

S1 Fig. Murine and human proinflammatory cytokine analysis. Murine and human proinflammatory profiles from the medium after 48-hour culture (n = 3). Mouse cytokines are displayed on the left y-axis in blue and human cytokines on the right y-axis in red. Upon analysis, (b) murine IL2p70 expression was significantly downregulated for islets co-cultured with Ad-MSCs (1:2000) compared to control islets (*p<0.05, ANOVA) (mean ± s.e.m). IL-1β, IL-6, IL-10, and tumor necrosis factor (TNF)-α expression was detected, but no significance difference was demonstrated amongst groups (p>0.05, ANOVA). Data represented (mean ± s.d). (TIFF)

S1 Table. Kidney Islet Engraftment Insulin Content and Immunohistochemistry. Kidney bearing grafts were removed from mice ≥ 60 days post islet transplant (200 islets cultured 48-hours prior to transplant). Islet graft insulin content were similar for animals co-transplanted with islets with Ad-MSCs and islets alone (n = 3, p>0.05, t-test). Immunohistochemistry insulin and glucagon content in islet grafts were similar amongst islets transplanted with or without Ad-MSCs (200 islets, 1:2000 Ad-MSCs: islets alone n = 4 and Ad-MSCs n = 5) (p>0.05, t-test). Data represented (mean ± s.e.m). (PDF)

Acknowledgments

Funding for this study was provided by the Diabetes Research Institute Foundation of Canada (DRIFCan) and the Canadian Institute of Health Research (CIHR PS 14889). A. Gamble is supported through Alberta Diabetes Institute Blanch Graduate Award and Gladys Woodrow Wirtanen Studentship. A. R. Pepper is supported by the Alberta Innovates—Health Solutions (AIHS) Postdoctoral Fellowship Grant 201400496. A. Bruni is supported by Canadian Institutes of Health Research—Proof of Principle Grant 144255 and Stem Cell Network (SCN). A. A is supported by Canadian Institutes of Health Research -Operating Grant (CIHR MOP 125921), A.M.J. Shapiro is supported through SCN Grant NCESCN CTRA FY17/CT5 and NCESCN DTRA FY17/DT6; AIHS Proof of Principle 144255 and Collaborative Research and Innovation Opportunities (CROI) Team funding Grant 201201154; the Juvenile Diabetes Research Fund Canadian Clinical Trial Network (JDRF CCTN) and the Diabetes Research Institute Foundation Canada (DRIFCan).

Author Contributions

Data curation: Anissa Gamble, Rena Pawlick, A. M. James Shapiro.

Formal analysis: A. M. James Shapiro.

Investigation: Anissa Gamble, A. M. James Shapiro.
Methodology: Anissa Gamble, Rena Pawlick, Andrew R. Pepper, Antonio Bruni, Gregory S. Korbutt, A. M. James Shapiro.

Supervision: Peter A. Senior, Gregory S. Korbutt, A. M. James Shapiro.

Visualization: Anissa Gamble.

Writing – original draft: Anissa Gamble, A. M. James Shapiro.

Writing – review & editing: Anissa Gamble, Rena Pawlick, Andrew R. Pepper, Adetola Adesida, Peter A. Senior, Gregory S. Korbutt, A. M. James Shapiro.

References

1. Hering BJ, Clarke WR, Bridges ND, Eggerman TL, Alejandro R, Bellin MD, et al. Phase 3 Trial of Transplantation of Human Islets in Type 1 Diabetes Complicated by Severe Hypoglycemia. Diabetes Care. 2016; 39(7):1230–40. https://doi.org/10.2337/dc15-1988 PMID: 27208344.

2. Emamauelle JA, Shapiro AM. Factors influencing the loss of beta-cell mass in islet transplantation. Cell transplantation. 2007; 16(1):1–8. Epub 2007/04/18. PMID: 17436849.

3. Kanak MA, Takita M, Kunnathodi F, Lawrence MC, Levy MF, Naziruddin B. Inflammatory response in islet transplantation. Int J Endocrinol. 2014; 2014:451035. https://doi.org/10.1155/2014/451035 PMID: 24883060; PubMed Central PMCID: PMC4021753.

4. Biarnes M, Montolio M, Nacher V, Raurell M, Soler J, Montanya E. Beta-cell death and mass in syngeneically transplanted islets exposed to short- and long-term hyperglycemia. Diabetes. 2002; 51(1):66–72. PMID: 11756324.

5. Eich T, Eriksson O, Lundgren T, Nordic Network for Clinical Islet T. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med. 2007; 356(26):2754–5. https://doi.org/10.1056/NEJMc070201 PMID: 17596618.

6. Hematti P, Kim J, Stein AP, Kaufman D. Potential role of mesenchymal stromal cells in pancreatic islet transplantation. Transplant Rev (Orlando). 2013; 27(1):21–9. https://doi.org/10.1016/j.trre.2012.11.003 PMID: 23290684.

7. Park KS, Shim EY, Choi BK, Moon C, Kim SH, Kim YS, et al. Cartilage oligomeric matrix protein-angiopoietin-1 enhances angiogenesis of isolated islet and maintains normoglycemia following transplantation. Transplant Proc. 2010; 42(7):2653–7. https://doi.org/10.1016/j.transproceed.2010.04.048 PMID: 20832563.

8. Phinney DG, Prockop DJ. Concise review: mesenchymal stem/multipotent stromal cells: the state of transdifferentiation and modes of tissue repair—current views. Stem Cells. 2007; 25(11):2896–902. https://doi.org/10.1634/stemcells.2007-0637 PMID: 17901396.

9. Yeung TY, Seeberger KL, Kin T, Adesida A, Jomha N, Shapiro AM, et al. Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines. PLoS One. 2012; 7(5):e38189. https://doi.org/10.1371/journal.pone.0038189 PMID: 22664860; PubMed Central PMCID: PMC3364233.

10. Ding Y, Xu D, Feng G, Bushell A, Muschel RJ, Wood KJ. Mesenchymal stem cells prevent the rejection of fully allogenic islet grafts by the immunosuppressive activity of matrix metalloproteinase-2 and -9. Diabetes. 2009; 58(8):1797–806. https://doi.org/10.2337/db09-0317 PMID: 19509016; PubMed Central PMCID: PMC2712800.

11. Ito T, Itakura S, Todorov I, Rawson J, Asari S, Shintaku J, et al. Mesenchymal stem cell and islet co-transplantation promotes graft revascularization and function. Transplantation. 2010; 89(12):1438–45. PMID: 20566773.

12. Rackham CL, Vargas AE, Hawkes RG, Amisten SJ, Persaud SJ, Austin AL, et al. Annexin A1 Is a Key Modulator of Mesenchymal Stromal Cell-Mediated Improvements in Islet Function. Diabetes. 2016; 65(1):129–39. https://doi.org/10.2337/db15-0990 PMID: 26470781.

13. Gruber R, Kandler B, Holzmann P, Vogele-Kadletz M, Lopert U, Fischer MB, et al. Bone marrow stromal cells can provide a local environment that favors migration and formation of tubular structures of endothelial cells. Tissue Eng. 2005; 11(5–6):896–903. https://doi.org/10.1089/ten.2005.11.896 PMID: 15988229.

14. Liu M, Han ZC. Mesenchymal stem cells: biology and clinical potential in type 1 diabetes therapy. J Cell Mol Med. 2008; 12(4):1155–68. https://doi.org/10.1111/j.1582-4934.2008.00289.x PMID: 18298656; PubMed Central PMCID: PMC365657.

15. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic mediators. J Cell Biochem. 2006; 98(5):1076–84. https://doi.org/10.1002/jcb.20886 PMID: 16619257.
16. Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008; 3(4):e1886. https://doi.org/10.1371/journal.pone.0001886 PMID: 18382669; PubMed Central PMCID: PMCPMC2270908.

17. Yamamoto T, Horiguchi A, Ito M, Nagata H, Ichii H, Ricordi C, et al. Quality control for clinical islet transplantation: organ procurement and preservation, the islet processing facility, isolation, and potency tests. J Hepatobiliary Pancreat Surg. 2009; 16(2):131–6. https://doi.org/10.1007/s00534-009-0064-z PMID: 19242650.

18. Yamamoto T, Ricordi C, Messinger S, Sakuma Y, Miki A, Rodriguez R, et al. Deterioration and variability of highly purified collagenase blends used in clinical islet isolation. Transplantation. 2007; 84(8):997–1002. https://doi.org/10.1097/01.tp.0000284979.48497.de PMID: 17989605.

19. Kin T, Senior P, O’Gorman D, Richer B, Salam A, Shapiro AM. Risk factors for islet loss during culture prior to transplantation. Transpl Int. 2008; 21(11):1029–35. https://doi.org/10.1111/j.1342-2277.2008.00719.x PMID: 18564983.

20. Nyqvist D, Kohler M, Wahlstedt H, Berggren PO. Donor islet endothelial cells participate in formation of functional vessels within pancreatic islet grafts. Diabetes. 2005; 54(8):2287–93. PMID: 16046293.

21. Korsgren O, Lundgren T, Feldin M, Foss A, Isaksson B, Pernert J, et al. Optimising islet engraftment is critical for successful clinical islet transplantation. Diabetologia. 2008; 51(2):227–32. https://doi.org/10.1007/s00125-007-0868-9 PMID: 18040664.

22. Shapiro AM, Pokrywczynska M, Ricordi C. Clinical pancreatic islet transplantation. Nat Rev Endocrinol. 2017; 13(5):268–77. https://doi.org/10.1038/nrendo.2016.178 PMID: 27833848.

23. Fraker C, Montelongo J, Szust J, Khan A, Ricordi C. The use of multiparametric monitoring during islet cell isolation and culture: a potential tool for in-process corrections of critical physiological factors. Cell transplantation. 2004; 13(5):497–502. PMID: 15565862.

24. Hayward JA, Ellis CE, Seeberger K, Lee T, Salama B, Mulet-Sierra A, et al. Cotransplantation of Mesenchymal Stem Cells With Neonatal Porcine Islets Improve Graft Function in Diabetic Mice. Diabetes. 2017; 66(5):1312–21. https://doi.org/10.2337/db16-1068 PMID: 28246290.

25. Rackham CL, Dhadda PK, Le Lay AM, King AJ, Jones PM. Preculturing Islets With Adipose-Derived Mesenchymal Stromal Cells Is an Effective Strategy for Improving Transplantation Efficiency at the Clinically Preferred Intraportal Site. Cell Med. 2014; 7(1):37–47. https://doi.org/10.3727/215517914X680047 PMID: 26858891; PubMed Central PMCID: PMCPMC4733844.

26. Rackham CL, Dhadda PK, Simpson SJS, Godazgar M, King AJF, Jones PM. Composite Mesenchymal Stromal Cell Islets: Implications for Transplantation via the Clinically Preferred Intraportal Route. Transplant Direct. 2018; 4(4):e354. https://doi.org/10.1097/TXD.0000000000000778 PMID: 29707625; PubMed Central PMCID: PMCPMC5908463.

27. Weiss WM, Mulet-Sierra A, Kunze M, Jomha NM, Adesida AB. Coculture of mesenchymal and mesenchymal stem cells in simulated microgravity. NPJ Microgravity. 2017; 3:28. https://doi.org/10.1038/s41526-017-0032-x PMID: 29147680; PubMed Central PMCID: PMCPMC5681589.

28. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006; 8(4):315–7. https://doi.org/10.1080/14653240600855905 PMID: 16923606.

29. Cabrera O, Jacques-Silva MC, Berman DM, Fachado A, Echeverri F, Poo R, et al. Automated, high-throughput assays for evaluation of human pancreatic islet function. Cell transplantation. 2008; 16 (10):1039–48. PMID: 18351020; PubMed Central PMCID: PMCPMC3529176.

30. Merani S, Tosco C, Ermannuille J, Shapiro AM. Optimal implantation site for pancreatic islet transplantation. Br J Surg. 2008; 95(12):1449–61. https://doi.org/10.1002/bjs.6391 PMID: 18991254.

31. Linn T, Schmitz J, Hauck-Schmalenberger I, Lai Y, Bretzel RG, Brandhorst H, et al. Ischaemia is linked to inflammation and induction of angiogenesis in pancreatic islets. Clin Exp Immunol. 2006; 144 (2):179–87. https://doi.org/10.1111/j.1365-2249.2006.03066.x PMID: 16634789; PubMed Central PMCID: PMCPMC1809653.

32. Brissova M, Powers AC. Revascularization of transplanted islets: can it be improved? Diabetes. 2008; 57(9):2269–71. https://doi.org/10.2337/db08-0814 PMID: 18753672; PubMed Central PMCID: PMCPMC2518476.

33. Zhang N, Richter A, Suriawinata J, Harbaran S, Altomonte J, Cong L, et al. Elevated vascular endothelial growth factor production in islets improves islet graft vascularization. Diabetes. 2004; 53(4):963–70. PMID: 15047611.

34. Gaia-Lopez BL, Pepper AR, Pawlick RL, O’Gorman D, Kin T, Bruni A, et al. Antiaging Glycopeptide Protects Human Islets Against Tacrolimus-Related Injury and Facilitates Engraftment in Mice. Diabetes. 2016; 65(2):451–62. https://doi.org/10.2337/db15-0764 PMID: 26981598.
35. Nilsson B, Ekdahl KN, Korsgren O. Control of instant blood-mediated inflammatory reaction to improve islets of Langerhans engraftment. Curr Opin Organ Transplant. 2011; 16(6):620–6. https://doi.org/10.1097/MOT.0b013e32834ec293 PMID: 21971510.

36. Berney T. Islet culture and counter-culture. Commentary on: Effect of short-term culture on functional and stress-related parameters in isolated human islets by Ihm et al. Transpl Int. 2009; 22(5):531–3. PMID: 19459231.

37. J.C. Mesenchymal Stem Cells Promote Islet Survival In Vitro and Function In Vivo. CellR4. 2013; 1(2):382.

38. Park KS, Kim YS, Kim JH, Choi B, Kim SH, Tan AH, et al. Trophic molecules derived from human mesenchymal stem cells enhance survival, function, and angiogenesis of isolated islets after transplantation. Transplantation. 2010; 89(5):509–17. https://doi.org/10.1097/TP.0b013e3181c7dc99 PMID: 20125064.

39. He Y, Zhang D, Zeng Y, Ma J, Wang J, Guo H, et al. Bone Marrow-Derived Mesenchymal Stem Cells Protect Islet Grafts Against Endoplasmic Reticulum Stress-Induced Apoptosis During the Early Stage After Transplantation. Stem Cells. 2018. https://doi.org/10.1002/stem.2823 PMID: 29569832.

40. Jung EJ, Kim SC, Wee YM, Kim YH, Choi MY, Jeong SH, et al. Bone marrow-derived mesenchymal stromal cells support rat pancreatic islet survival and insulin secretory function in vitro. Cytotherapy. 2011; 13(1):19–29. https://doi.org/10.3109/14653249.2010.518608 PMID: 21124900.

41. Dietrich I, Crescenzi A, Chaib E, D’Albuquerque LA. Trophic effects of adipose derived stem cells on Langerhans islets viability—Review. Transplant Rev (Orlando). 2015; 29(3):121–6. https://doi.org/10.1016/j.trre.2015.04.006 PMID: 26002997.

42. Tanaka T, Kojima D, Mera T, Matsumoto M, Yasunami Y, Yanase T. Expansion of transplanted islets in mice by co-transplantation with adipose tissue-derived mesenchymal stem cells. Heliyon. 2018; 4(5):e00632. https://doi.org/10.1016/j.heliyon.2018.e00632 PMID: 29872765; PubMed Central PMCID: PMCPMC5986537.

43. Ohmura Y, Tanemura M, Kagawauchi M, Machida T, Tanida T, Deguchi T, et al. Combined transplantation of pancreatic islets and adipose tissue-derived stem cells enhances the survival and insulin function of islet grafts in diabetic mice. Transplantation. 2010; 90(12):1366–73. https://doi.org/10.1097/TP.0b013e3181fbb3a1 PMID: 21076379.

44. Imamura H, Adachi T, Kon T, Ono S, Sakai Y, Adachi T, et al. An engineered cell sheet composed of human islets and human fibroblast, bone marrow-derived mesenchymal stem cells, or adipose-derived mesenchymal stem cells: An in vitro comparison study. Islets. 2018; 1:1–11. https://doi.org/10.1080/19382014.2018.1445948 PMID: 29608395.

45. Schive SW, Mirlashari MR, Hasvold G, Wang M, Josefson D, Gullesstad HP, et al. Human Adipose-Derived Mesenchymal Stem Cells Respond to Short-Term Hypoxia by Secreting Factors Beneficial for Human Islets In Vitro and Potentiate Anti-diabetic Effect In Vivo. Cell Med. 2017; 9(3):103–16. https://doi.org/10.3727/215517917X693401 PMID: 28713640; PubMed Central PMCID: PMCPMC5509020.

46. Cavallari G, Olivi E, Bianchi F, Neri F, Foroni L, Valente S, et al. Mesenchymal stem cells and islet co-transplantation in diabetic rats: improved islet graft revascularization and function by human adipose tissue-derived stem cells preconditioned with natural molecules. Cell transplantation. 2012; 21(12):2771–81. https://doi.org/10.3727/096368912X637046 PMID: 22472472.

47. Johansson U, Rasmussen I, Niclou SP, Forslund N, Gustavsson L, Nilsson B, et al. Formation of composite endothelial cell-mesenchymal stem cell islets: a novel approach to promote islet revascularization. Diabetes. 2008; 57(9):2393–401. https://doi.org/10.2337/db07-0981 PMID: 18519803; PubMed Central PMCID: PMCPMC2518490.

48. Rackham CL, Dhadda PK, Chagastelles PC, Simpson SJ, Dattani AA, Bowe JE, et al. Pre-culturing islets with mesenchymal stromal cells using a direct contact configuration is beneficial for transplantation outcome in diabetic mice. Cytotherapy. 2013; 15(4):449–59. https://doi.org/10.1016/j.jcyt.2012.11.008 PMID: 23231626.

49. Karaoz E, Genc ZS, Demircan PC, Aksoy A, Duruksu G. Protection of rat pancreatic islet function and viability by coculture with rat bone marrow-derived mesenchymal stem cells. Cell Death Dis. 2010; 1:e36. https://doi.org/10.1038/cddis.2010.14 PMID: 21364643; PubMed Central PMCID: PMCPMC3033204.

50. de Souza BM, Boukas AP, Oliveira FD, Reis KP, Ziegelmann P, Bauer AC, et al. Effect of co-culture of mesenchymal stem/stromal cells with pancreatic islets on viability and function outcomes: a systematic review and meta-analysis. Islets. 2017; 9(2):30–42. https://doi.org/10.1080/19382014.2017.1286434 PMID: 28151049; PubMed Central PMCID: PMCPMC5345749.

51. Sharon M, Klausner RD, Cullen BR, Chizzonite R, Leonard WJ. Novel interleukin-2 receptor subunit detected by cross-linking under high-affinity conditions. Science. 1986; 234(4778):859–63. PMID: 3095922.
52. Siegel JP, Sharon M, Smith PL, Leonard WJ. The IL-2 receptor beta chain (p70): role in mediating signals for LAK, NK, and proliferative activities. Science. 1987; 238(4823):75–8. PMID: 3116668.

53. Sandler S, Bendtzen K, Eizirik DL, Welsh M. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology. 1990; 126(2):1288–94. https://doi.org/10.1210/en-d-126-2-1288 PMID: 2404746.

54. Sart S, Tsai AC, Li Y, Ma T. Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties, and applications. Tissue Eng Part B Rev. 2014; 20(5):365–80. https://doi.org/10.1089/ten.TEB.2013.0537 PMID: 24168395; PubMed Central PMCID: PMCPMC4185975.